A global distribution network for AMOLAB

For the Apulian start-up, 2022 closes with agreements in the USA, China, the Philippines and Russia, as well as Greece, Spain, Portugal and the Baltic countries.

Negotiations started for Thailand, Japan and the countries of the Persian Gulf

LECCE – From European Union countries to China and the United States of America. The distribution network of the Innovative SME Amolab, born in Lecce in 2011 as a spin-off of the National Research Council, has become international in scope, as a result of the acceleration in 2022 which will lead to further expansionary effects in the next year.

Amolab has strengthened the distribution channels of both the portable ultrasound scanner SensUS Lung, which allows a non-invasive, fast and automated investigation of the state of lung health and is able to provide an index of the percentage risk that this is caused by Covid- 19, and of the SensUS Touch ultrasound system, which performs safe and non-invasive monitoring of all stages of labor through indicators of the progression of the fetus along the birth canal. The supply network of LaborSim, the intrapartum ultrasound simulator developed to facilitate the training of medical and obstetric staff, was also expanded.

“2022 was an important year that allowed us to cross the borders of the European Union”, says the CEO of Amolab, engineer Salvatore Calcagnile. “SensUS Lung was used for post Covid-19 lung screenings in the Greek islands, in support of public health. The staff of the 'Evangelista' hospital in Athens visited patients who could not reach the Athens office, employing the Amolab ultrasound machine, as it was easily moved from one place to another thanks to its light weight and small size,” he explains he. “After the channels in Spain and Portugal, we are also physically present in the Baltic countries where there is an export manager who works alongside the back office activities”, he continues.

Looking to the eastern part of the geographical map, Amolab has concluded a contract in China aimed at completing the tests for the purposes of the NMDA (formerly CFDA) marking, necessary for distribution: "We plan to close the process within a year and a half for both devices".

By the end of 2022, contracts for the distribution of ultrasound systems will be signed in seven countries in the Eurasian area, after a series of contacts initiated in recent months, while the procedures relating to the Gulf countries should be completed in 2023.

Looking west, Amolab aims at the USA: "We have started a collaboration with MedScaler, a Dutch company specialized in the commercial and regulatory sectors for biomedical devices, with the aim of reaching the United States of America in 2023 and exporting ultrasound machines", adds engineer Calcagnile.

The feedback obtained from the LaborSim simulator was also important which, after being presented to the medical and obstetric staff of various Italian hospitals, landed in the Philippines and has already been used on the occasion of the international congress of obstetrics and gynecology which took place in Manila in the past weeks.

“Participation in the World Forum for Medicine 'Medica', in Düsseldorf, Germany, allowed us to start negotiations with China, Thailand and Japan in view of the possible distribution of LaborSim, and this makes us very pleased as it testifies to the interest for training in hospitals and universities for the correct execution of trans-perineal ultrasound, the purpose for which the simulator was designed".

In parallel with the distribution activity, the Amolab team is engaged on the research front: "The goal we intend to achieve in 2023 is linked to a new module for the SensUS Lung, in order to diagnose pleural effusion", anticipates the CEO of Amolab. "We have launched a multi-center study, in collaboration with national and international realities, to support the medical-scientific community", concludes engineer Calcagnile.